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Abstract
Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase 3 family, is activated by
oxidative stress. The death-signaling pathway mediated by ASK1 is inhibited by DJ-1, which is linked to recessively inherited
Parkinson’s disease (PD). Considering that DJ-1 deficiency exacerbates the toxicity of the mitochondrial complex I inhibitor
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we sought to investigate the direct role and mechanism of ASK1 in
MPTP-induced dopamine neuron toxicity. In the present study, we found that MPTP administration to wild-type mice
activates ASK1 in the midbrain. In ASK1 null mice, MPTP-induced motor impairment was less profound, and striatal
dopamine content and nigral dopamine neuron counts were relatively preserved compared to wild-type littermates.
Further, microglia and astrocyte activation seen in wild-type mice challenged with MPTP was markedly attenuated in
ASK1
2/2 mice. These data suggest that ASK1 is a key player in MPTP-induced glial activation linking oxidative stress with
neuroinflammation, two well recognized pathogenetic factors in PD. These findings demonstrate that ASK1 is an important
effector of MPTP-induced toxicity and suggest that inhibiting this kinase is a plausible therapeutic strategy for protecting
dopamine neurons in PD.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder in which dopaminergic neurons of the substantia nigra
bear the brunt of the pathology. A consistent biochemical
abnormality in this brain region documented in postmortem
studies is oxidative stress with distinct markers of damage to
cellular proteins, lipids and DNA [1]. These findings, along with
the realization that agents that are toxic to dopaminergic neurons
in vitro and in vivo cause increased intracellular levels of reactive
oxygen species, have led to the use of those toxins to generate
animal models of PD. Among these toxins, MPTP is a
mitochondrial complex I inhibitor that causes parkinsonian
features in humans and primates, and recapitulates dopaminergic
deficits in the nigrostriatal pathway of mice [2,3]. Therefore,
MPTP is widely used as a tool to study the molecular events that
lead to degeneration of dopaminergic neurons in animal models of
PD and to test potentially neuroprotective agents.
Several genes have been linked to familial forms of PD. Among
these, DJ-1, which causes recessively inherited disease when
mutated, encodes a neuroprotective protein that has antioxidant
activity [4]. In addition, we reported previously that DJ-1 achieves
its cytoprotective function by interfering with the activation of
Apoptosis Signal-Regulating Kinase 1 (ASK1) signaling pathway
[5], suggesting that the latter might be involved in the pathogenesis
of PD.
ASK1 is a member of the MAP3 kinase family that activates
JNK and p38 kinase pathways [6,7]. In addition to Fas-induced,
Daxx-mediated activation [8], ASK1 is activated by various
stimuli including oxidative stress [9,10], endoplasmic reticulum
stress [11] and TNF-a [12], and relays those signals to JNK and
p38 [8] leading to apoptosis [9]. A number of studies have
suggested that ASK1 is functional in neural tissues. Its mRNA is
expressed in brain, including in cortex, hippocampus, olfactory
bulb and striatum [13], and expression of a constitutively active
form of ASK1 induces neurite outgrowth in the rat pheochromo-
cytoma PC12 cell line [14]. In addition, the requirement of ASK1
activation has been demonstrated in an ALS mouse model
expressing mutant form of SOD1 [15]. In a recent postmortem
study of PD affected brains, ASK1 was found to be activated in
substantia nigra neurons compared to control brains [16]. Further,
ASK1
2/2 primary neurons are resistant to cell death induced by
ER stress, proteasome dysfunction, and expanded polyglutamine
expression [11], and ASK1 knockdown using shRNA in the mouse
nigra diminishes 6-hydroxydopamine toxicity [16]. Thus, ASK1 is
a key player in mediating the effects of various cellular insults.
Here, we show that MPTP administration activates ASK1 in
the substantia nigra of wild-type mice, while deleting the ASK1
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biochemical, histopathological and behavioral analyses. Our
results indicate that blocking ASK1 expression can mitigate the
dopaminergic neuron loss that follows MPTP intoxication and
suppresses glial activation in the nigra and striatum. These findings
suggest that ASK1 signaling plays an important role in MPTP-
induced toxicity in mice by linking the oxidative stress generated
by MPTP and the associated neuroinflammation. Controlling
ASK1 activity may ultimately help design new neuroprotective
therapeutic interventions for PD and other neurodegenerative
disorders in which oxidative stress plays a significant pathogenetic
role.
Results
ASK1 is activated by oxidative stress in cultured cells and
in vivo
Since ASK1 is known to be a key player in oxidative stress-
induced cell signaling, we examined whether MPTP-induced
dopaminergic cell death is associated with ASK1 activation. First,
dopaminergic neuroblastoma SH-SY5Y cells were challenged with
MPP
+, and processed for in vitro kinase assay of ASK1. A
significant increase in ASK1 activity was seen as early as
10 minutes after MPP
+ treatment (Fig. 1A). We also observed
ASK1 activation in primary rat cortical neurons following H2O2
challenge (1 mM) detected by a transient increase in the amount of
phosphorylated ASK1 (Fig. 1B) as reported previously [17]. Next,
we investigated the levels of phosphorylated ASK1 following
MPTP administration into mice. Wild-type C57BL/6J mice were
injected with MPTP (20 mg/kg every 2 h64) or saline intraper-
itoneally and sacrificed 90 min after the last injection. Ventral
midbrains containing substantia nigra pars compacta were
processed for Western blotting using anti-phophorylated ASK1
antibody. MPTP administration significantly increased phosphor-
ylated ASK1 level compared to saline-treated animals (Fig. 1C)
consistent with previous reports [18,19]. These findings indicate
that ASK1 is activated in vitro and in vivo after insults that produce
oxidative stress.
ASK1 null mice are relatively resistant to MPTP
To address the role of ASK1 in the pathogenesis of PD, we
compared the susceptibility of wild-type and ASK1
2/2 mice to
MPTP. First, loss of ASK1 expression was confirmed by Western
blotting of substantia nigra tissue lysates from ASK1
2/2 mice
(Fig. 2A). MPTP was administered over 5 days (30 mg/kg/day)
and animals were sacrificed 14 days after the last injection. The
integrity of nigral dopaminergic neurons was assessed by
stereological counting of TH positive neurons. Compared to
about 35% loss of TH-positive neurons due to MPTP in wild-type
mice, this figure was only about 13% in ASK1
2/2 animals
(Fig. 2B). On the other hand, stereological counting of TH-
negative, Nissl-stained neurons showed no change after MPTP in
either group (Fig. 2C). The finding that TH-positive neurons
decreased while TH-negative/Nissl stained neurons did not
increase after MPTP compared to saline indicates degeneration
of TH-positive neurons rather than merely decreased TH
expression. Representative immunohistochemical images show
marked degeneration of nigral dopaminergic neurons in MPTP
challenged wild-type mice but a significantly attenuated effect in
ASK1
2/2 mice (Fig. 2D).
Striatal dopamine depletion is an important measure of
dopaminergic neuron degeneration in PD and MPTP models.
Two weeks after MPTP administration, striatal dopamine content
decreased down to 28% in wild-type mice compared to saline
injected animals. On the other hand, dopamine content in
ASK1
2/2 mice decreased down to 45% (p,0.05) (Fig. 3A).
Striatal tyrosine hydroxylase content measured by ELISA also
showed a smaller decline after MPTP exposure in ASK1
2/2 mice
compared to wild-type animals (32% residual TH in wild-type
mice compared to 53% in ASK1
2/2 mice; p,0.01) (Fig. 3B).
Immunohistochemical staining of the striatum for TH revealed a
profile consistent with the ELISA data indicating that striatal
dopaminergic terminals of ASK1
2/2 mice were relatively spared
compared to their wild-type counterparts (Fig. 3C).
To exert its toxicity in vivo, MPTP is first converted to MPP
+ by
MAO-B activity. To confirm that the attenuated response of
ASK1
2/2 mice to MPTP is not due to altered MPTP metabolism
in this mouse line, we measured striatal MPP
+ levels after MPTP
intoxication. Ninety minutes after a single IP injection of 30 mg/
kg MPTP, striatal MPP
+ levels measured by HPLC were
3.6560.42 ng/mg protein (n=8) for ASK1
2/2 mice compared
with 3.8860.55 ng/mg protein for wild-type mice (n=6). This
lack of a difference indicates that MPTP metabolism is not altered
as a result of ASK1 deletion, and, therefore, this possibility cannot
Figure 1. Oxidative stress-induced ASK1 activation. (A) ASK1
activation by MPP
+. SH-SY5Y cells were challenged with 5 mM MPP
+
and ASK1 activity measured by in vitro kinase (IVK) assay. Total ASK1
expression was checked by Western blotting. The bar graph on the
right shows quantification of band intensities. (B) ASK1 phosphorylation
with hydrogen peroxide treatment. Rat primary cortical neurons were
challenged with 1 mM H2O2 followed by Western blotting for phospho-
ASK1. The bar graph on the right shows quantification of the Western
blot data. (C) ASK1 phosphorylation in MPTP-injected mice. Wild-type
mice were injected with MPTP (20 mg/kg every 2 h64) or saline
intraperitoneally and sacrificed 90 minutes after the last injection.
Midbrains containing substantia nigra from four saline treated mice and
5 MPTP challenged mice were homogenized and lysed for Western
blotting with phospho-ASK1 antibody and total ASK1 antibody. The bar
graph shows quantification of the Western blot data. * p,0.05.
doi:10.1371/journal.pone.0029935.g001
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2/2 mice to MPTP
toxicity.
The motor manifestations of PD are due to the marked
reduction in striatal dopamine content caused by the loss of
dopaminergic nerve terminals in the striatum. Since ASK1
deficiency is associated with an attenuated response to MPTP
toxicity, we investigated if ASK1
2/2 mice have a better locomotor
and behavioral performance following MPTP intoxication com-
pared to wild-type littermates. First, performance on the rotarod
was evaluated 1 day after saline or MPTP (20 mg/kg every 2 h64)
treatment. Compared to the poor performance of wild-type mice
after MPTP, ASK1
2/2 mice intoxicated with MPTP had
longer latency to fall from the rotating bar indicating a better
performance (Fig. 4A). Second, nest-building behavior, which
requires orofacial and forelimb movements, is impaired after
MPTP [20] and is dopamine-dependent [21], was evaluated 2
days after saline or MPTP (20 mg/kg every 2 h64) administra-
tion. Compared with the 72% impairment in nest building ability
in wild-type mice lesioned with MPTP vs saline, ASK1
2/2
animals had significant preservation of this behavior after MPTP
(Fig. 4B,C). These results are consistent with the biochemical and
stereological indices of dopaminergic system preservation in
MPTP lesioned ASK1
2/2 mice.
Comparison of non-lesioned ASK1
2/2 mice with wild-type
littermates following saline administration showed a modest
elevation of striatal dopamine content (17.260.62 vs
15.260.43 ng/mg, respectively; p,0.03) as described previously
[22]. This was associated with a parallel increase in nigral
dopamine neuron count (49846347 vs 32156276, respectively;
p,0.05). Behaviorally, these animals are also reported to be
hyperactive in a novel environment and to have superior
performance on the rotarod [22], although their trend of better
performance in this study was not significant (Fig. 4A, B).
MPTP-induced glial activation is blunted in ASK1 null
mice
Microglia activation is associated with the pathogenesis of PD
and is an important player in MPTP toxicity [23,24]. To
determine if ASK1 is involved in MPTP-induced microglia
activation, wild-type and ASK1
2/2 mice were subjected to the
Figure 2. Nigral dopaminergic neurons are protected against
MPTP in ASK1
2/2 mice. (A) Western blot for ASK1 in substantia nigra
tissue lysates from wild-type and ASK1
2/2 mice shows loss of the
specific band in the latter group (arrow). The asterisk marks a
nonspecific band. (B) Stereological counting of TH positive nigral
dopamine neurons following MPTP or saline administration. * p,0.05.
(C) Number of Nissl stained TH negative neurons. Saline-WT (n=5),
Saline-ASK1
2/2 (n=5), MPTP-WT (n=4), MPTP-ASK1
2/2 (n=5). (D)
Representative images of TH immunohistochemistry of midbrain
sections from wild-type and ASK1
2/2 mice treated with saline or MPTP.
Scale bar=200 mm.
doi:10.1371/journal.pone.0029935.g002
Figure 3. Indices of dopamine nerve terminal integrity in the
striatum show protection against MPTP in ASK1
2/2 mice. (A)
Striatal dopamine content following MPTP or saline administration.
*p ,0.05. (B) TH content measured by ELISA in striatal tissue. ** p,0.01.
Saline-WT (n=5), Saline-ASK1
2/2 (n=5), MPTP-WT (n=4), MPTP-ASK1
2/2
(n=5). (C) Representative images of immunohistochemical images for TH
in striatum. Scale bar=200 mm.
doi:10.1371/journal.pone.0029935.g003
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brains were analyzed 1 day and 3 days after the last injection.
Striatal and nigral sections were studied immunohistochemically
using the microglial marker Iba1. Compared to the robust
induction of Iba1 positive cells in the nigra of wild-type mice
following MPTP, this response was significantly attenuated in
ASK1
2/2 mice (Fig. 5A, C). In the striatum, the activation of
microglia after MPTP intoxication observed in wild-type mice was
also markedly blunted in ASK1
2/2 animals (Fig. 5B, D).
Cyclooxygenase 2 (COX-2), the inducible form of the rate-
limiting enzyme in prostaglandin synthesis, is increased in PD
brains [25] and reportedly mediates microglia activation and
subsequent dopamine neuron degeneration in the mouse MPTP
model [26,27]. Consistent with the significant attenuation in
microglial activation following MPTP challenge in ASK1
2/2,
COX-2 expression detected by Western blotting with midbrain
lysates showed minimal induction following MPTP administration
in ASK1
2/2 mice compared to the robust induction one day after
MPTP in wild-type animals (Fig. 5E). The latter finding suggests
that ASK1 is a key player in MPTP-induced COX-2 expression
and subsequent microglia activation.
We also assessed activation of astroglial cells using immunohis-
tochemistry for glial fibrillary acidic protein (GFAP) 1 day and 3
days after acute MPTP exposure. MPTP induced strong activation
of GFAP positive cells in the nigra (Fig. 6A) and striatum (Fig. 6B)
of wild-type mice particularly at 3 days, compared to a
significantly blunted response in both these brain regions of
ASK1
2/2 mice, suggesting that ASK1 is required for MPTP-
induced astrocyte activation as well.
Discussion
In the present study, we have found that ASK1 deficiency
partially protects the nigrostriatal dopaminergic system against
MPTP-induced neurotoxicity and inhibits microglia and astrocyte
activation. We also show that the behavioral benefits of ASK1
deletion correlate well with the observed cellular protection. These
findings collectively suggest that ASK1 plays an important role in
MPTP-induced toxicity in vivo.
Evidence is accumulating that chronic inflammation exacer-
bates the pathology in a number of neurodegenerative diseases
including PD [28]. The innate immune cells of the brain, such as
reactive astrocytes and microglia are abundant in the substantia
nigra of PD [29], indicating a robust inflammatory state.
Additionally, reactive microglial cells are seen in the basal ganglia
in the 6-OHDA, MPTP and rotenone induced animal models of
PD [30,31,32]. Further, a-synuclein, which aggregates in the
characteristic inclusions in vulnerable neurons in PD patient
brains, activates microglia and astrocytes in several PD models
[33,34,35,36]. However, it remains controversial whether activa-
tion of glial cells is favorable or detrimental to neurons. Our data
suggest a detrimental role of activated glia in the neurodegener-
ative process, as the neuroprotection conferred by ASK1
deficiency correlates with a markedly attenuated glial response.
The mechanism by which MPTP leads to microglia activation
remains obscure. Relevant to earlier reports that COX-2 mediates
MPTP-induced microglia activation and subsequent dopamine
neuron toxicity [26,27], our results show that ASK1 is required for
MPTP-induced COX-2 expression. This suggests that the role of
ASK1 in regulating microglia activation is in part through
regulating COX-2 expression [25]. Contrary to ASK1 deletion,
JNK ablation reportedly does not interfere with microglia
activation in the MPTP model, although targeted deletion of
JNK protects dopaminergic neurons from MPTP toxicity [26].
Therefore, we speculate that the signal that leads to microglia
activation is relayed from ASK1 to molecules other than JNK. In
light of this notion, it is noteworthy that the phosphorylation of
p38 MAP kinase, which is another kinase downstream of ASK1
[7], is observed within dopamine neurons in MPTP-lesioned mice,
whereas JNK activation occurs primarily in microglia [37].
Further, the increased staining of phosphorylated p38 kinase in
surviving nigral dopamine neurons in human brain sections from
PD patients compared to age-matched controls provides further
support for a role of p38 kinase in the degeneration of
dopaminergic neurons [37]. A more direct relationship between
ASK1 and p38 kinase has been shown in a study demonstrating
that ASK1 is required for lipopolysaccharide (LPS)-induced
activation of p38 but not of JNK in splenocytes and dendritic
cells [38].
ASK1 is required for Toll-like receptor 4 (TLR4)-mediated
mammalian innate immunity [38]. Splenocytes and dendritic cells
isolated from ASK1
2/2 mice lose the ability to express
Figure 4. Preserved behavioral responses in MPTP-treated ASK1
2/2 mice compared to MPTP-treated wild-type mice. (A) Performance
on the Rotarod test one day post-MPTP. Saline-WT (n=3), Saline-ASK1
2/2 (n=6), MPTP-WT (n=3), MPTP-ASK1
2/2 (n=4). * p,0.05. (B, C) Nest
building behavior two days post-MPTP scored after 18 hours in the cage with a square cotton Nestlet. Saline-WT (n=3), Saline-ASK1
2/2 (n=6), MPTP-
WT (n=3), MPTP-ASK1
2/2 (n=4). * p,0.05.
doi:10.1371/journal.pone.0029935.g004
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2/2 mice. (A, B) Immunohistochemistry with the microglial marker Iba1
(polyclonal, 1:2,000) of nigral (SNc) and striatal (ST) sections. Scale bar=100 mm. (C) Quantification of nigral Iba1 immunopositivity. * p,0.001. (D)
Quantification of striatal Iba1 immunopositivity. * p,0.001. Quantifications were done using ImageJ. (E) MPTP-induced COX-2 expression is
attenuated in ASK1
2/2 mice. Midbrains containing substantia nigra were homogenized and lysed for Western blotting for COX-2. Samples from two
different mice per group are shown. * p,0.001. WT-Saline (n=4), WT-MPTP-1 day (n=4), WT-MPTP-3 day (n=4); ASK1
2/2-Saline (n=3), ASK1
2/2-
MPTP-1 day (n=4), ASK1
2/2-MPTP-3 day (n=3).
doi:10.1371/journal.pone.0029935.g005
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following LPS stimulation. In addition, ASK1 is required for
chemokine production in astrocytes through several TLRs, and
ASK1 deficiency attenuates neuroinflammation in the experimen-
tal autoimmune encephalomyelitis model in mice [39]. Collec-
tively, these results indicate that ASK1 is expressed in these
immune/glial cells and plays a role in their cell signaling.
Therefore, we postulate that the attenuated glial activation upon
MPTP exposure in ASK1
2/2 mice results from the effects of
ASK1 deficiency in these cells. Based on Western blotting and
RT-PCR with primary cell cultures, ASK1 is expressed in both
microglia and astrocytes as well as in neurons including TH
Figure 6. MPTP induced astrogilal activation is suppressed in ASK1
2/2 mice. (A, B) Immunohistochemistry for GFAP in nigral (SNc) and
striatal (ST) sections. Scale bar=100 mm. (C) Quantification of nigral GFAP immunopositivity. * p,0.01; **,0.001. (D) Quantification of striatal GFAP
immunopositivity. ** p,0.001. Quantifications were done using ImageJ. WT-Saline (n=4), WT-MPTP-1 day (n=4), WT-MPTP-3 day (n=4); ASK1
2/2-
Saline (n=3), ASK1
2/2-MPTP-1 day (n=4), ASK1
2/2-MPTP-3 day (n=3).
doi:10.1371/journal.pone.0029935.g006
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that ASK1 in dopamine neurons relays the signal(s) originated
from MPP
+ to produce the molecule(s) responsible for glial
activation, although the nature of these molecules remains to be
characterized. It is conceivable that a-synuclein released from
dying dopamine neurons contributes to this event [33,34]. In
addition, ASK1 in glial cells may propagate the signal(s) conveyed
from sick neurons finally resulting in glial activation and, in turn,
further dopamine neuron injury.
In conclusion, our data provide evidence that ASK1 mediates
microglia and astrocyte activation and MPTP-induced neurotox-
icity, and that deletion of ASK1 prevents degeneration of DA
neurons and glial activation. These findings suggest that ASK1
may serve as a potential target for the development of therapeutic
interventions to slow or halt PD progression.
Materials and Methods
Cell and primary cultures
Human neuroblastoma SH-SY5Y cells (ATCC) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS) (Invitrogen) in a CO2 incubator at 37uC.
To prepare primary neuronal cultures, cortical tissue from E18
embryos of Sprague Dawley rats (Charles River) were recovered as
described previously [40] under a protocol (# I08-034) approved
by the Institutional Animal Care and Use Committee at the
UMDNJ-Robert Wood Johnson Medical School. Tissues were
minced and cells dissociated mechanically by gentle passaging
through a flame-polished pasteur pipette in Neurobasal medium
(Invitrogen). Cells were then passed through a strainer (45 mM
pore size) and rinsed once in final culture medium (Neurobasal
medium with B27 serum-free supplements, 0.5 mM L-glutamine,
0.1 IU/ml penicillin and 10 mg/ml streptomycin). Dissociated
cells were plated at a density of 2610
5 per cm
2 in 100 mg/ml poly-
D-lysine coated plates, and 1 mM cytosine arabinoside was added
to the medium.
In vitro ASK1 Activity Assay
Cells were challenged with 5 mM MPP
+ (Sigma) for the
indicated times, and lysates were processed for immunoprecipita-
tion with anti-ASK1 antibody (H-300, Santa Cruz Biotechnology).
The immunoprecipitated complex was used for in vitro kinase
assay in a reaction buffer consisting of 20 mM Tris-HCl (pH 7.5),
20 mM MgCl2,5mCi [c-
32P] ATP for 20 min at 30uC using
myelin basic protein (MBP) (40 mg/ml) as substrate. Samples were
resolved in SDS-PAGE and subjected to autoradiography.
Animals and MPTP Administration
ASK1 knockout mice were maintained on the C57BL/6J
background as described previously [7]. All animals were handled
in accordance with the NIH guidelines for the use of laboratory
animals under a protocol (# I07-011-2) approved by the
Institutional Animal Care and Use Committee at the UMDNJ-
Robert Wood Johnson Medical School. Three-month-old wild-
type and ASK1
2/2 male mice were challenged intraperitoneally
with MPTP dissolved in sterile saline. Control animals received
saline injections. Injection paradigms and doses are described in
the Results section.
Western Blot
Cells and tissues were lysed with RIPA buffer (50 mM Tris,
pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium
deoxycholate) containing phosphatase inhibitor cocktail set II
(Calbiochem, La Jolla, CA) and protease inhibitor cocktail set V
(Calbiochem, La Jolla, CA). Lysates were separated in 4–12%
gradient gel (Invitrogen). Primary antibodies used for Western
blots and immunohistochemistry in these studies were as follows:
anti-ASK1 (H-300) (Santa Cruz Biotechnology), anti-phospho-
ASK1 (generated against the ASK1 epitope that contains p-
Thr845) [41], anti-TH (Sigma), anti-GFAP (DAKO), anti-Iba1
(Wako), anti-COX-2 (BD Bioscience), and anti-b-actin (Sigma).
Secondary antibodies (Sigma), anti-rabbit IgG-HRP or anti-mouse
IgG-HRP were used with an enhanced chemiluminescence (ECL)
kit (PerkinElmer LAS) for signal generation on X-ray film.
Immunohistochemistry and Stereology
Mice were perfused transcardially with PBS, and brains were
removed and post-fixed in 4% paraformaldehyde at 4uC
overnight. Free-floating, 40 mm thick coronal sections were
incubated with the indicated primary antibodies overnight,
followed by staining with the ABC kit (Vector Laboratories).
For counting nigral dopaminergic neurons, coronal 40-mm-thick
sections were cut through the entire substantia nigra (SN). The SN
pars compacta and medial ventral tegmental area regions were
outlined for neuron counting according to previous anatomical
demarcations of the midbrain dopaminergic neurons in the mouse
[42]. Every fourth section through the rostral–caudal extent of the
SN was stained with an antibody against tyrosine hydroxylase
(TH, 1:4000; Sigma) and processed with the ABC method. Tissue
sections were counterstained with cresyl violet, a Nissl stain, and
cover-slipped. StereoInvestigator software (version 8.0. Micro-
Brightfield Inc., Williston, VT) was used to count TH-immuno-
reactive (TH-IR) cells and Nissl-stained cells. Cells were counted
with a 1006 oil immersion objective (1.3 NA) using a Leica
DMRE microscope. The cell counting frame was 5065065 mm
with a 1 mm upper and lower guard zone. A cell was defined as a
TH-IR soma with a clearly visible unstained nucleus. For Nissl-
stained cells, a cell was defined as a non-TH-containing soma in
focus within the counting frame. The TH cell counts were taken
from 6 sections, spaced 4 apart (120 mm) and 200–250 cells were
counted in the SN on one side of the brain. For Nissl cell counting,
the same sections were examined. TH-containing cells represent
dopaminergic neurons, and cresyl-violet stained neurons represent
all other nondopaminergic neurons.
Measurement of Striatal Dopamine, MPP
+ and TH
Mice were killed after MPTP or saline injections at time points
specified in the Results section, and their striata were quickly
dissected. Striatal dopamine and its metabolites were measured by
HPLC-electrochemical detection as described previously [43].
Striatal levels of MPP
+ were measured by HPLC using UV
detection. Striatal tyrosine hydroxylase content was measured by
an enzyme-linked immunosorbent assay method [44].
Behavior Assessments
Motor coordination and motor learning were measured by the
rotarod test. Mice were placed on a rotating cylinder (diame-
ter=4.5 cm) with a coarse surface for a firm grip and tested for
three trials with an accelerating speed of 0.2 rpm/second,
increasing from 4 to 40 rpm. A cut-off time of 3 min and an
inter-trial interval of 60 min were used. The latency of time spent
on the rod before falling was measured.
To assess nest-building performance, each mouse was housed in
a cage containing a single block of nesting material (NestletsTM,
Ancare Corp) for 18 h. Each cage was then scored blindly
depending on the condition of nesting material on a scale ranging
from 0=non shredded to 5=maximally shredded [45].
Role of ASK1 in MPTP Toxicity and Glia activation
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Two-sample comparisons were carried out using Student’s t-test
and multiple comparisons were done using one-way ANOVA
followed by the Newman-Keuls multiple range test. Data are
presented as means 6 SEM and statistically significant differences
were accepted at the p,0.05 level.
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